The reduction of spontaneous and stimulated growth hormone (GH) secretion in obesity could reflect an increase of the inhibitory effect of insulin growth factor I (IGF-I) on somatotroph secretion. DESIGN: In the present study we aimed to verify the effect of low dose recombinant human IGF-I (20 mg=kg subcutaneously (s.c.) at 0 min) on 3 h-spontaneous GH secretion (mGHc, 0 -180 min) and on the GH response to growth hormone releasing hormone (GHRH) (1 mg=kg i.v. at þ 180 min) in obesity. SUBJECTS: Five obese women with abdominal adiposity (OB, age, mean AE s.e.m.: 31 AE 7.13 y; BMI: 32.04 AE 3.69 kg=m 2 ) and eight age-matched lean women (NW, 28.3 AE 1.2 y; 20.1 AE 0.5 kg=m 2 ) were studied. RESULTS: The mGHc and GHRH-induced GH response in OB (1.0 AE 0.7 mg=l; AUC 180 -270 min : 688.6 AE 202.4 mg=l min, respectively) were lower than in NW (2.6 AE 0.8 mg=l, 1315.9 AE 189.9 mg=l min, respectively, P < 0.05). The administration of rhIGF-I increased circulating IGF-I levels in OB and NW to the same extent (339.0 AE 50.39 and 420.3 AE 30.5 mg=l, respectively). The rhIGF-I administration did not affect mGHc in OB or NW (1.1 AE 0.9 and 3.2 AE 1.0 mg=l, respectively) but inhibited (P < 0.05) the GH response to GHRH in OB (324.2 AE 153.1 mg=l) and NW (730.2 AE 288.1 mg=l). CONCLUSIONS: Our study shows that the administration of low dose rhIGF-I reduces the somatotroph responsiveness to GHRH in obesity as well as in normal subjects.
Introduction
In obesity, spontaneous growth hormone (GH) secretion is reduced, 1 reflecting either neuroendocrine 2 -4 or metabolic abnormalities. 5 -7 Moreover, obese subjects show impaired GH increase to provocative stimuli, including growth hormone releasing hormone (GHRH), 1 normal inhibition after pirenzepine or somatostatin, 8 but not after glucose. 9 Little is known about the somatotroph sensitivity of obese individuals to the insulin-like growth factor-I (IGF-I) negative feedback which, in normal subjects, is able to inhibit the GH response to GHRH, arginine and growth hormone-releasing peptides (GHRPs) 10, 11 acting either directly at the pituitary level through activation of IGF-1 receptors or through CNS-mediated mechanisms. 12, 13 Based on the foregoing, the aim of the present study was to verify the effect of low dose rhIGF-I on the GH response to GHRH in obesity. Total IGF-I, insulin and glucose levels were also measured.
Materials, subjects and methods
Five obese women with abdominal adiposity (OB, age, mean AE s.e.m.: 31 AE 7.13 y; body mass index (BMI): 32.04 AE 3.69 kg=m 2 ) were studied in the morning at 0830 -0900 after an overnight fast and the results compared with those recorded for eight normal lean women (NW, age, 28.3 AE 1.2 y; 20.1 AE 0.5 kg=m 2 ) in whom the inhibitory effect of rhIGF-I had been already shown.
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All subjects underwent the following tests at least 3 days apart in random order: (1) placebo (s.c. at 0 min) þ GHRH (Geref, Serono, Roma, Italy, 1 mcg=kg i.v. at þ 180 min); (2) rhIGF-I administration (rhIGF-I, Pharmacia and Upjohn, Stockholm, Sweden, 20 mg=kg s.c. at 0 min) þ GHRH.
Blood samples were drawn basally and then every 30 min up to 270 min for serum GH, IGF-I, insulin and plasma glucose determination. All measurements were made in duplicate by immunoradiometric assay (GH) or radioimmunoassay (IGF-I and insulin) or by glucose-oxidase colorimetric method (glucose). GH levels are expressed as mean concentration before GHRH administration (mGHc 0 -180 min ) and as areas under curves (AUC 180 -270 min , calculated by trapezoidal integration) afterwards. The statistical analysis was carried out using non-parametric analysis of variance (Mann -Whitney ANOVA), and Wilcoxon signed rank test. The results are expressed as mean AE s.e.m.
Results
Basal IGF-I levels in OB and NW were similar (220 AE 54.35 vs 274.4 AE 25.3 mg=l). The mGHc 0 -180 min (1.0 AE 0.7 mg=l) and GHRH-induced GH response in OB (AUC 180 -270 min : 688.6 AE 202.4 mg=l min) were lower (P < 0.05) than in NW (2.6 AE 0.8 mg=l, 1315.9 AE 189.9 mg=l min, respectively). The administration of rhIGF-I increased circulating IGF-I levels in OB and NW to the same extent (339.0 AE 50.39 and 420.3 AE 30.5 mg=l, respectively). The rhIGF-I administration did not affect mGHc 0 -180 min in OB or NW, but inhibited (P < 0.05) the GH response to GHRH in OB (324.2 AE 153.1 mg=l) as well as in NW (730.2 AE 288.1 mg=l). The percentage decrease of the responses was similar in the two groups. RhIGF-I administration did not modify insulin and glucose levels either in OB or NW.
Discussion
The present study shows that the subcutaneous administration of low dose rhIGF-I in obesity reduces the somatotroph responsiveness to GHRH. These findings indicate that somatotroph sensitivity to the inhibitory effect of rhIGF-I is preserved in obesity and makes the existence of an enhanced negative IGF-I feedback effect in this condition unlikely.
